Early cytomegalovirus reactivation is associated with a poorer outcome after an alemtuzumab-based reduced-intensity conditioning allogeneic stem cell transplant

被引：0
|
作者：
Noriega, V. [1 ]
Cutino-Moguel, T. [1 ]
Zuckerman, M. [1 ]
Potter, V. [1 ]
Barabino, L. [1 ]
Raj, K. [1 ]
McLornan, D. [1 ]
de Lavallade, H. [1 ]
Devereux, S. [1 ]
Marsh, J. [1 ]
Sudhanva, M. [1 ]
Mufti, G. [1 ]
Pagliuca, A. [1 ]
机构：
[1] Kings Coll Hosp, London, England
来源：
BONE MARROW TRANSPLANTATION | 2013年 / 48卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S299 / S300
页数：2
相关论文
共 50 条
  • [1] Myeloablative after reduced-intensity conditioning allogeneic stem cell transplant: toxicity and outcome?
    Cordonnier, C
    Hamladji, R
    Genitsch, A
    Gratwohl, A
    BONE MARROW TRANSPLANTATION, 2005, 35 : S361 - S362
  • [2] Alemtuzumab-based reduced-intensity conditioning for XIAP deficiency
    Kobushi, Hirokazu
    Umeda, Katsutsugu
    Hiejima, Eitaro
    Kato, Kentaro
    Sugimoto, Mayumi
    Kanegane, Hirokazu
    Takita, Junko
    PEDIATRICS INTERNATIONAL, 2023, 65 (01)
  • [3] Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation
    Avivi, I
    Chakrabarti, S
    Kottaridis, P
    Kyriaku, C
    Dogan, A
    Milligan, DW
    Linch, D
    Goldstone, AH
    Mackinnon, S
    BONE MARROW TRANSPLANTATION, 2004, 34 (02) : 137 - 142
  • [4] Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation
    I Avivi
    S Chakrabarti
    P Kottaridis
    C Kyriaku
    A Dogan
    D W Milligan
    D Linch
    A H Goldstone
    S Mackinnon
    Bone Marrow Transplantation, 2004, 34 : 137 - 142
  • [5] Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia - A Single-Institution Experience
    Ramasamy, Karthik
    Mahmood, Shameem
    Lim, ZiYi
    Corderoy, Sophie
    Devereux, Stephen
    Mufti, Ghulam J.
    Pagliuca, Antonio
    Schey, Stephen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (02): : 242 - 245
  • [6] Incidence and outcome of Adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab
    Avivi, I
    Chakrabarti, S
    Milligan, DW
    Waldmann, H
    Hale, G
    Osman, H
    Ward, KN
    Fegan, CD
    Yong, K
    Goldstone, AH
    Limb, DC
    MacKinnon, S
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (03) : 186 - 194
  • [7] Impact of chimerism conversion kinetics on transplant outcome after reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation
    Michallet, M
    Le, QH
    Michallet, AS
    Nicolini, F
    Thiebaut, A
    Tavernier, E
    Rafii, H
    Mahmoudi, S
    Revesz, D
    Praire, A
    Gadolet, E
    Raus, N
    Dubois, V
    BONE MARROW TRANSPLANTATION, 2005, 35 : S205 - S205
  • [8] Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies
    Chiesa, Robert
    Veys, Paul
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (03) : 255 - 266
  • [9] Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation
    Barba, Pere
    Luis Pinana, Jose
    Valcarcel, David
    Querol, Luis
    Martino, Rodrigo
    Sureda, Anna
    Briones, Javier
    Delgado, Julio
    Brunet, Salut
    Sierra, Jorge
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (11) : 1439 - 1446
  • [10] Features of Epstein-Barr virus reactivation after reduced-intensity conditioning allogeneic stem cell transplantation
    Peric, Z.
    Chevallier, P.
    Guillaume, T.
    Delaunay, J.
    Ayari, S.
    Dubruille, V.
    Le Gouill, S.
    Mahe, B.
    Gastinne, T.
    Blin, N.
    Saulquin, B.
    Milpied, N.
    Vrhovac, R.
    Harousseau, J. L.
    Moreau, P.
    Coste-Burel, M.
    Imbert-Marcille, B. M.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S287 - S287
12345